Aiping Zhou

机构：National Cancer Center, Shanghai East Hospital, Southeast University, Taizhou University, Nanjing University · ORCID：0000-0002-6617-6653

发表论文 111 篇 · 总被引 1500 次 · h-index 22

代表论文

• CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial (2025 · Nature Medicine · 被引 40)
• Minimal residual disease profiling predicts pathological complete response in esophageal squamous cell carcinoma (2024 · Molecular Cancer · 被引 21)
• Safety and efficacy of IBI343 (anti-claudin18.2 antibody-drug conjugate) in patients with advanced pancreatic ductal adenocarcinoma or biliary tract cancer: Preliminary results from a phase 1 study. (2024 · Journal of Clinical Oncology · 被引 19)
• Regorafenib monotherapy or combined with an immune-checkpoint inhibitor as later-line treatment for metastatic colorectal cancer: a multicenter, real-world retrospective study in China (2024 · BMC Cancer · 被引 10)
• Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer (2025 · Human Vaccines & Immunotherapeutics · 被引 8)
• The GRAPHS-CRAFITY score: a novel efficacy predictive tool for unresectable hepatocellular carcinoma treated with immunotherapy (2024 · La radiologia medica · 被引 7)